Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/20/2025

Prasugrel Dosing and Administration Guidelines

Patient Selection and Dosing Considerations

  • The American College of Cardiology recommends that prasugrel is generally not recommended in patients ≥75 years due to increased risk of fatal and intracranial bleeding, except in high-risk elderly patients with diabetes or history of prior MI 2, 3
  • Patients weighing <60 kg have increased exposure to the active metabolite and higher bleeding risk, and may require a reduced maintenance dose of 5 mg daily 2, 3
  • Prior history of stroke or transient ischemic attack (TIA) is a contraindication for prasugrel use 2, 6

Special Population Considerations

  • The American College of Cardiology suggests considering the 5 mg maintenance dose in elderly patients if prasugrel is used 5, 3
  • For patients with UA/NSTEMI, the loading dose should be administered after coronary anatomy is defined 1

Duration of Therapy and Monitoring

  • The American College of Cardiology recommends at least 12 months of prasugrel therapy for patients receiving drug-eluting stents (DES) and at least 1 month for patients receiving bare-metal stents (BMS) 4
  • Consider discontinuing prasugrel at least 7 days before any planned surgery to reduce bleeding risk 3, 4
  • Prasugrel is associated with higher bleeding risk compared to clopidogrel, with a significant increase in fatal bleeding 4
  • Additional risk factors for bleeding include body weight <60 kg, propensity to bleed, and concomitant use of medications that increase bleeding risk 3

REFERENCES

6

Prasugrel Therapy Duration and Management [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025